Dashboard
Manage Tickers

PLRX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-pliant-therapeutics-maintains-38-price-target
HC Wainwright & Co. Reiterates Buy on Plia...
09/13/2024 10:58:20

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-the-european-respiratory-society-international-congress-2024
Pliant Therapeutics Presents Data From Its...
09/10/2024 12:16:03

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of nove...

leerink-partners-assumes-pliant-therapeutics-at-outperform-announces-price-target-of-33
Leerink Partners Assumes Pliant Therapeuti...
09/09/2024 13:01:18

Leerink Partners analyst Faisal Khurshid assumes Pliant Therapeutics (NASDAQ:PLRX) with a Outperform rating and announces Pr...

pliant-therapeutics-announces-4-upcoming-presentations-at-the-ers-international-congress-2024
Pliant Therapeutics Announces 4 Upcoming P...
08/26/2024 13:11:35

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of nove...

hc-wainwright--co-maintains-buy-on-pliant-therapeutics-raises-price-target-to-38
HC Wainwright & Co. Maintains Buy on Plian...
08/12/2024 09:42:56

HC Wainwright & Co. analyst Ed Arce maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and raises the price target f...

cantor-fitzgerald-reiterates-overweight-on-pliant-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
08/08/2024 14:29:58

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Overweight.

oppenheimer-maintains-outperform-on-pliant-therapeutics-lowers-price-target-to-45
Oppenheimer Maintains Outperform on Pliant...
08/08/2024 12:11:42

Oppenheimer analyst Jeff Jones maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target fro...

needham-reiterates-buy-on-pliant-therapeutics-maintains-38-price-target
Needham Reiterates Buy on Pliant Therapeut...
08/08/2024 09:55:43

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

pliant-therapeutics-q2-eps-092-misses-085-estimate
Pliant Therapeutics Q2 EPS $(0.92) Misses ...
08/07/2024 21:21:48

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of...

needham-reiterates-buy-on-pliant-therapeutics-maintains-38-price-target
Needham Reiterates Buy on Pliant Therapeut...
07/16/2024 17:25:56

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

hc-wainwright--co-reiterates-buy-on-pliant-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on Plia...
07/16/2024 12:32:35

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.

pliant-therapeutics-shares-long-term-data-from-the-integris-psc-phase-2a-trial-demonstrating-bexotegrast-was-well-tolerated-at-320-mg-with-continued-antifibrotic-and-anti-cholestatic-activity-displayed-across-multiple-measures
Pliant Therapeutics Shares Long-Term Data ...
07/15/2024 12:02:45

Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events...

hc-wainwright--co-reiterates-buy-on-pliant-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on Plia...
06/07/2024 11:09:22

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.

pliant-therapeutics-to-present-data-from-its-bexotegrast-program-at-the-easl-international-liver-congress-june-5-8-2024
Pliant Therapeutics To Present Data From I...
06/06/2024 12:06:14

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of nove...

reported-earlier-pliant-therapeutics-presented-bexotegrast-program-data-at-american-thoracic-society-2024-international-conference
Reported Earlier, Pliant Therapeutics Pres...
05/22/2024 07:51:21

In an oral presentation, Gregory P. Cosgrove, M.D., FCCP, Vice President of Clinical Development at Pliant Therapeutics provide...

hc-wainwright--co-reiterates-buy-on-pliant-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on Plia...
05/15/2024 18:00:30

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.

pliant-therapeutics-drug-trial-shows-promise-in-reversing-lung-fibrosis-in-patients
Pliant Therapeutics' Drug Trial Shows Prom...
05/14/2024 14:39:54

Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung coll...

pliant-therapeutics-announces-positive-topline-data-from-a-phase-2a-collagen-pet-imaging-clinical-trial-of-bexotegrast-in-patients-with-idiopathic-pulmonary-fibrosis
Pliant Therapeutics Announces Positive Top...
05/14/2024 11:34:34

citigroup-maintains-buy-on-pliant-therapeutics-lowers-price-target-to-44
Citigroup Maintains Buy on Pliant Therapeu...
05/07/2024 17:35:34

Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target from $45...

these-analysts-revise-their-forecasts-on-pliant-therapeutics-following-q1-earnings
These Analysts Revise Their Forecasts On P...
05/07/2024 15:53:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION